Pharmacokinetic allometric scaling of coagulation factors and tissue-type plasminogen activators

Haemophilia

Volumn 15, Issue 5, 2009, Pages 1109-1117

  Mahmood, I ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clearance; Coagulation factors; Elimination half life; Interspecies pharmacokinetic scaling; Tissue type plasminogen activators; Volume of distribution

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PAMITEPLASE; RETEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ALLOMETRY; ANALYTIC METHOD; ARTICLE; CLEARANCE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HALF LIFE TIME; HUMAN; NONHUMAN; PHARMACOKINETIC ALLOMETRIC SCALING; PREDICTION; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; BLOOD COAGULATION FACTORS; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HUMANS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; SPECIES SPECIFICITY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 69949089085     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02054.x     Document Type: Article

References (27)

1. Chappell WR, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res 1991; 20: 1-116.
2. Sarrus PF, Rameaux JF. Rapport sur un memoire addressee l'Academie royale de Medecine. Bull Acad R Med Paris 1839; 3: 1094-100.
3. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary -comparative paradigm. Drug Metab Rev 1984; 15: 1071-121.
4. Boxenbaum H, D'Souza RW. Interspecies pharmacokinetic scaling, biological design and neoteny. Adv Drug Res 1990; 19: 139-96.
5. Shargel L, Yu ABC. Introduction to Pharmacokinetics, Applied Biopharmaceutics and Pharmacokinetics. Norwalk, CT: Appleton & Lange, 1993.
6. Gibaldi M, Perrier D. Noncompartmental Analysis Based on Statistical Moment Theory, Pharmacokinetics. New York, NY: Marcel Dekker, 1982.
7. Mahmood I. Interspecies Scaling of Clearance. Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling. Rockville, MD: Pine House Publishers, 2005.
8. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991; 8: 1351-9.
9. Mahmood I. Interspecies scaling of protein drugs: Prediction of clearance from animals to humans. Pharm Sci 2004; 93: 177-85.
10. Mahmood I. Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J Pharm Sci 2009 [Epub ahead of print].
11. Tang H, Hussain A, Leal M, Mayersohn M, Fluhler E. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 2007; 35: 1886-93.
12. Mahmood I. Interspecies scaling of therapeutic proteins. In: Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling. Rockville, MD: Pine House Publishers, 2005: 244-58.
13. Boxenbaum H. Comparative pharmacokinetics of benzodiazepines in dog and man. J Pharmacokinet Biopharm 1982; 10: 411-26.
14. Caldwell GW, Masucci JA, Yan Z, Hageman W. Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur J Drug Metab Pharmacokinet 2004; 29: 133-43.
15. Reigner BG, Blesch KS. Estimating the starting dose for entry into humans: Principles and practice. Eur J Clin Pharmacol 2002; 57: 835-45.
16. Boxenbaum H, Dilea C. First-time-in-human dose selection: Allometric thoughts and perspectives. J Clin Pharmacol 1995; 35: 957-66.
17. Mahmood I, Green MD, Fisher JE. Selection of the first-time dose in humans: Comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 2003; 43: 692-7.
18. Mahmood I. First-in-human dose selection. In: Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling. Rockville, MD: Pine House Publishers, 2005: 259-87.
19. Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 1996; 136: 75-8.
20. Brinkhous K, Sandberg H, Widlund L et al. Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. Semin Thromb Hemost 2002; 28: 269-72.
21. Keith JC, Ferranti TJ, Misra B et al. Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog. Thromb Haemost 1994; 73: 101-5.
22. McCarthy K, Stewart P, Sigman J et al. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 2002; 87: 824-30.
23. Björkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994; 46: 325-32.
24. Oikawa K, Kamimura H, Watanabe T, Miyamoto I, Higuchi S. Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Thromb Res 2001; 101: 493-500.
25. Oikawa K, Watanabe T, Miyamoto I, Higuchi S. Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. Xenobiotica 2000; 30: 993-1003.
26. Martin U, Kohler J, Sponer G, Strein K. Pharmacokinetics of the Novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non-human primates. Fibrinolysis 1992; 6: 39-43.
27. Martin U, Mollendorff EV, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 1991; 66: 569-74.